Zoekresultaten - 4 results
Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma.
the prospective multicentre DAWN-plasma trial, adult patients hospitalised with COVID-19 were randomised to 4 units of open-label convalescent plasma combined with standard of care (intervention group) ...
Closing schools for SARS-CoV-2: a pragmatic rapid recommendation
experts, clinicians and researchers, produced this recommendation in compliance with the standards for trustworthy rapid guidelines. The recommendation is based on data collected through national ...
A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the DAWn-Plasma trial.
Therapy COVID-19 Female Global Burden of Disease Hospitalization Humans Immunization, Passive Male mortality Respiration, Artificial SAFETY SARS-CoV-2 Standard of Care Treatment Outcome Abstract: ...
SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data.
laboratories when blind-testing 15 plasma samples. Calibration of titres in relation to the reference reagent and standard curve obtained by testing a dilution series reduced the inter-laboratory variability ca ...